Filtered By:
Infectious Disease: Hepatitis B

This page shows you your search results in order of date.

Order by Relevance | Date

Total 149 results found since Jan 2013.

Pharmacokinetics of Jnj-73763989 And Jnj-56136379 (Bersacapavir) In Participants With Moderate Hepatic Impairment
This article is protected by copyright. All rights reserved.PMID:36786053 | DOI:10.1002/jcph.2214
Source: The Journal of Clinical Pharmacology - February 14, 2023 Category: Drugs & Pharmacology Authors: Thomas N Kakuda Atef Halabi Gernot Klein Madhu Sanga Carine Guinard-Azadian Monika Kowalik Katja Nedoschinsky Julius Nangosyah Emmanuel Njumbe Ediage Vera Hillewaert Peter Verboven Ivo Goris Jan Snoeys Martyn Palmer Michael Biermer Source Type: research

Lnc-AIFM2-1 promotes HBV immune escape by acting as a ceRNA for miR-330-3p to regulate CD244 expression
Chronic hepatitis B (CHB) virus infection is a major risk factor for cirrhosis and hepatocellular carcinoma (HCC). Hepatitis B virus (HBV) immune escape is regulated by the exhaustion of virus-specific CD8+ T cells, which is associated with abnormal expression of negative regulatory molecule CD244. However, the underlying mechanisms are unclear. To investigate the important roles of non-coding RNAs play in CD244 regulating HBV immune escape, we performed microarray analysis to determine the differential expression profiles of long non-coding RNAs (lncRNAs), microRNAs (miRNAs), and mRNAs in patients with CHB and patients wi...
Source: Frontiers in Immunology - February 9, 2023 Category: Allergy & Immunology Source Type: research

Screening of an epigenetic compound library identifies BRD4 as a potential antiviral target for hepatitis B virus covalently closed circular DNA transcription
In this study, we screened an epigenetic compound library in the cccDNA reporter cell line HepBHAe82, which produces the HA-tagged HBeAg in a cccDNA-dependent manner. Among the obtained hits, a bromodomain-containing protein 4 (BRD4) inhibitor MS436 exhibited marked inhibition of cccDNA transcription in both HBV stable cell line HepAD38 and HepG2-NTCP or primary human hepatocyte infection system under noncytotoxic concentrations. Chromatin immunoprecipitation (ChIP) assay demonstrated that MS436 dramatically reduced the enrichment of H3K27ac, an activating histone modification pattern, on cccDNA minichromosome. RNAseq diff...
Source: Antiviral Research - February 3, 2023 Category: Virology Authors: Xiaoyang Yu Quanxin Long Sheng Shen Zhentao Liu Jithin Chandran Junjie Zhang Hao Ding Hu Zhang Dawei Cai Elena S Kim Yufei Huang Haitao Guo Source Type: research

Pharmacokinetics, Safety, and Tolerability of the siRNA JNJ ‐73763989 in Healthy Chinese Adult Participants
AbstractJNJ-73763989, composed of the 2 short-interfering RNA triggers JNJ-73763976 and JNJ-73763924, targets all hepatitis B virus messenger RNAs, thereby reducing all viral proteins. In this phase 1, single-site, open-label, parallel-group, randomized study, participants were given 1 subcutaneous injection of JNJ-73763989 (100 or 200  mg) to investigate the pharmacokinetics, safety, and tolerability of JNJ-73763989 in healthy Chinese adult participants. Plasma and urine pharmacokinetic parameters were determined for each trigger up to 48 hours after dosing. Eighteen participants, 9 per dose group, were enrolled. The me...
Source: Clinical Pharmacology in Drug Development - November 23, 2022 Category: Drugs & Pharmacology Authors: Haiyan Li, Xiaoye Niu, Yu Zhang, Danning Zhang, Yanqing Zhang, Liqun Wang, Yongqing Miao, Yanxin Jiang, Jia Ji, Qiaoqiao Chen, Xiaoyun Wu, Emmanuel Njumbe Ediage, Thomas N. Kakuda, Michael Biermer Tags: Original Article Source Type: research

The cytoplasmic LSm1-7 and nuclear LSm2-8 complexes exert opposite effects on Hepatitis B virus biosynthesis and interferon responses
In this study, we used a Hepatitis B Virus (HBV) replication model and performed proteomic analyses to understand how HBV evades innate immunity as a function of cell cycle progression. Specifically, we performed proteomic analyses of HBV-replicating cells in G1/S and G2/M phases, as a function of IFN-α treatment. We identified that the conserved LSm (Like-Sm1-8) proteins were differentially regulated in HBV replicating cells treated with IFN-α. Specifically, in G2/M phase, IFN-α increased protein level of LSm1, the unique subunit of cytoplasmic LSm1-7 complex involved in mRNA decay. By contrast, IFN-α decreased LSm8, ...
Source: Frontiers in Immunology - August 9, 2022 Category: Allergy & Immunology Source Type: research

PreS/2-21-Guided siRNA Nanoparticles Target to Inhibit Hepatitis B Virus Infection and Replication
A viable therapy is needed to overcome the deadlock of the incurable chronic hepatitis B (CHB). The prolonged existence of covalently closed circular DNA (cccDNA) and integrated HBV DNA in the nucleus of hepatocytes is the root cause of CHB. As a result, it is critical to successfully suppress HBV DNA replication and eliminate cccDNA. RNA interference has been proven in recent research to silence the expression of target genes and thereby decrease HBV replication. However, siRNA is susceptible to be degraded by RNA enzymes in vivo, making it difficult to deliver successfully and lacking of tissue targeting. To exploit the ...
Source: Frontiers in Immunology - April 29, 2022 Category: Allergy & Immunology Source Type: research

Viruses, Vol. 14, Pages 657: HBsAg Loss as a Treatment Endpoint for Chronic HBV Infection: HBV Cure
ung Despite the availability of effective vaccines and antiviral therapy over the past two to three decades, chronic hepatitis B virus (HBV) infection remains a major global health threat as a leading cause of cirrhosis and liver cancer. Functional HBV cure defined as hepatitis B surface antigen (HBsAg) loss and undetectable serum HBV DNA is associated with improved clinical outcomes in patients with chronic HBV infection. However, spontaneous loss of HBsAg is rare and occurs in only 1% of all HBsAg-positive individuals annually. Furthermore, the rate of functional cure with currently available antiviral therapy is eve...
Source: Viruses - March 22, 2022 Category: Virology Authors: Maryam Moini Scott Fung Tags: Review Source Type: research

RNA interference as a novel treatment strategy for chronic hepatitis B infection
Clin Mol Hepatol. 2022 Feb 17. doi: 10.3350/cmh.2022.0012. Online ahead of print.ABSTRACTChronic hepatitis B (CHB) is a major cause of liver-related morbidity and mortality. Functional cure of CHB, defined as sustainable hepatitis B surface antigen (HBsAg) seroclearance, is associated with improved clinical outcomes. However, functional cure is rarely attainable by current treatment modalities. RNA interference (RNAi) by small-interfering RNA (siRNA) and anti-sense oligonucleotide (ASO) has been studied as a novel treatment strategy for CHB. RNAi targets post-transcriptional messenger RNAs and pregenomic RNAs to reduce hep...
Source: Clinical and molecular hepatology - February 17, 2022 Category: Gastroenterology Authors: Rex Wan-Hin Hui Lung-Yi Mak Wai-Kay Seto Man-Fung Yuen Source Type: research